Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities.
作者信息
Wolitz Rebecca E, Kesselheim Aaron S, Darrow Jonathan J
机构信息
Rebecca E. Wolitz is with the Moritz College of Law, The Ohio State University, Columbus. Jonathan J. Darrow and Aaron S. Kesselheim are with the Program on Regulation, Therapeutics, and Law, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Jonathan J. Darrow is also with the Department of Law & Taxation, Bentley University, Waltham, MA.
出版信息
Am J Public Health. 2022 Aug;112(8):1110-1114. doi: 10.2105/AJPH.2022.306888. Epub 2022 Jun 16.
Abstract
摘要
相似文献
1
Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities.美国政府利用专利促进公共卫生：克服非专利排他性
Am J Public Health. 2022 Aug;112(8):1110-1114. doi: 10.2105/AJPH.2022.306888. Epub 2022 Jun 16.
2
Experts warn drug industry, government about weaknesses in drug supply chain.专家就药品供应链的薄弱环节向制药行业和政府发出警告。
Am J Health Syst Pharm. 2003 Nov 1;60(21):2176, 2180, 2184. doi: 10.1093/ajhp/60.21.2176.
3
The End of "Patent Medicines"? Thoughts on the Rise of Regulatory Exclusivities.“成药专利”的终结？关于监管独占权兴起的思考。
Food Drug Law J. 2015;70(1):39-53.
4
A cheat sheet to navigate the complex maze of exclusivities in the United States.一份用于在美国错综复杂的专有权益迷宫中导航的备忘单。
Pharm Pat Anal. 2014 Jul;3(4):339-43. doi: 10.4155/ppa.14.30.
5
RU 486 and the politics of drug regulation in the United States and France.RU 486与美国和法国的药品监管政策
Cornell Int Law J. 1992;25:667-718.
6
Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.规范药品安全：美国食品药品监督管理局、优先适用权与公众健康。
JAMA. 2009 May 20;301(19):2036-7. doi: 10.1001/jama.2009.680.
7
The FDA: is it protecting the public with one hand tied behind its back?美国食品药品监督管理局：它是否在一只手被束缚的情况下保护公众？
Law Med Health Care. 1992 Fall;20(3):253-7. doi: 10.1111/j.1748-720x.1992.tb01199.x.
8
Corporate responsibility for recombinant DNA activities.重组DNA活动的企业责任。
Univ Toledo Law Rev. 1981 Summer;12(4):913-24.
9
FDA regulation of prescription drug advertising.美国食品药品监督管理局对处方药广告的监管。
JAMA. 1990 Nov 14;264(18):2424-5.
10
Vaccine liability in the Supreme Court: forging a social compact.最高法院中的疫苗责任：打造社会契约。
JAMA. 2011 May 11;305(18):1900-1. doi: 10.1001/jama.2011.615.
本文引用的文献
1
Government Pharmaceutical Development to Address High Prices: Challenges Ahead.政府药物研发以应对高药价：前路挑战重重。
Ther Innov Regul Sci. 2021 Sep;55(5):1103-1105. doi: 10.1007/s43441-021-00324-6. Epub 2021 Jul 14.
2
Drug Shortages and the Defense Production Act.药品短缺与《国防生产法》。
Am J Public Health. 2020 Oct;110(10):1504-1505. doi: 10.2105/AJPH.2020.305862.
3
The Pay-Twice Critique, Government Funding, and Reasonable Pricing Clauses.双重付费批评、政府资金与合理定价条款
J Leg Med. 2019 Apr-Jun;39(2):177-211. doi: 10.1080/01947648.2019.1648942.
4
Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: .欧盟促进仿制药发展的数据独占权例外与强制许可：
J Pharm Policy Pract. 2017 Jun 28;10:19. doi: 10.1186/s40545-017-0107-9. eCollection 2017.
5
Health Resources Priority and Allocations System (HRPAS). Interim final rule.卫生资源优先分配系统（HRPAS）。暂行最终规则。
Fed Regist. 2015 Jul 17;80(137):42408-23.
Zotero 插件